Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer

NCT06129422 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: NMK89

Sponsor

Nihon Medi-Physics Co., Ltd.